OBEZITE VE METABOLIK SENDROM
Özet
Obezite ve metabolik sendrom (MetS), modern toplumlarda artan sıklıkla görülen ve yaşam kalitesini düşüren önemli halk sağlığı sorunlarıdır. Beden Kütle İndeksi (BKİ) ve bel çevresi ölçümü ile tespiti önerilen obezite, insülin direnci ve düşük yoğunluklu enflamasyon aracılığıyla MetS gelişimine zemin hazırlamaktadır. Temel bileşenleri santral obezite, insülin direnci, dislipidemi, hipertansiyon ve glukoz metabolizması bozukluğu olan MetS; WHO, EGİR, ATP III ve IDF gibi çeşitli uluslararası kuruluşlarca farklı tanı kriterleriyle tanımlanmıştır. MetS gelişimi; aile öyküsü, ileri yaş, fiziksel inaktivite, sigara ve alkol kullanımı, kötü beslenme alışkanlıkları ve bazı ilaçlar gibi risk faktörleriyle ilişkilidir. Etiyopatogenezinde artmış serbest yağ asitleri, adinopektin azalması, TNF-alfa ve IL-6 gibi proenflamatuar sitokinlerin yükselmesi kritik rol oynamaktadır. Bu durum; Tip 2 Diyabet, kardiyovasküler hastalıklar (KVH) ve non-alkolik yağlı karaciğer hastalığı (NAYKH) riskini belirgin şekilde artırır. Takip ve tedavide agresif hayat tarzı değişiklikleri (diyet ve düzenli egzersiz) primer basamağı oluştururken; gerektiğinde metformin ile prediyabet yönetimi, antihipertansifler (ACE inhibitörleri/ARB) ve lipid düzenleyici medikal tedaviler uygulanmalıdır.
Referanslar
Jensen, M. (2020). Obesity. Lee Goldman (Ed.), Goldman-Cecil Medicine (1418-27). Philadelphia: Elsevier.
Bray G, Frühbeck G, Ryan D, et al. Management of Obesity. Lancet 2016; 387: 1947-56.
Jerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650.000 adults. Mayo Clin Proc 2014; 89: 335-45.
Kylin E. Studien’’uber das Hypertonie-Hypergly-kaemie-hyperurikaemie syndrom. Zentralbl Inn Med 1923; 44: 105-27.
Vague J. La differenciation sexuelle, facteur determinant des formes de I’obesite. Presse Medl 1947; 53: 339-40.
Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diapedes. Diabetologia 1965; 1: 37-8.
Haller H. Epidemiologie und assoziierte risikofaktoren der hyperlipoproteinamie(epidemiology and associated risk factors of hyperlipoproteinemia) Z Gesamte Inn Med 1977; 32: 124-28.
Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514–20.
Defronzo RA. İnsulin resistance: a multifacted syndrom responsble for NIDDM, obesity, hypertansion, dyslipidemia and atherosclerosis. Neth J Med 1997; 50: 191-97.
Hijerman I. The Metabolic cardiovascular syndrome: syndrom X, Reaven’s syndrom, İnsulin resistance syndrome, Atherothrombogenic syndrome. J Cardiovasc Pharmacol 1992;20: 5-10.
Alberti KG, Zimmet PZ. Definition, diagnosis and classifications1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
Balkau B, Charles MA. Comment on the provisionel report from the WHO consultation. Europen Group for the study of Insülin Resistance(EGİR). Diabet Med 1999; 16: 442-3.
Executive Summary of the Third Report of National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of heigh blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
Alberti G, Zimmet P, Shaw J et al. Worldwide definition of the metabolic syndrome. International Diabetes Federation Lancet 2005; 366: 1059-62.
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep 2018; 20:12.
2015 Obesity collaborators GBD. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017 Jul 6;377(1):13-27.
Ford ES, Giles WH, Dietz WH. Prevalance of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
National Center for Health Statistics, Division of Health Interview Statistics. Crude and age-adjusted percentage of civilian, noninstitutionalized adults with diagnosed diabetes, United States, 1980– 2010. National Center for Chronic Disease Prevention and Health Promotion, Ed. Atlanta, GA, Centers for Disease Control and Prevention, Division of Diabetes Translation, 2012.
Palaniappan LP, Wong EC, Shin JJ, et al. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. In J Obe. 2017;35:393–400.
Wang Y, Mi J, Shan X, et al. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obesity. 2007;31:177–88.
First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009 Jun; 32(6):1092-7.
Onat A, Sansoy V. Halkımızda koroner hastalığın baş suçlusu metabolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyoloji Dern Arş 2002; 30: 8-15.
Kozan Ö, Oğuz A, Abacı A, Erol Ç, Öngen Z, Temizhan A, Çelik Ş. Prevalance of the metabolic syndrome amond Turkish adults. Eur J Clin Nutrition 2007; 61: 548-53.
Eckel RH, Grundy SM, Zimmet PZ. Metabolik sendrom. Lancet 2005; 365: 1415.
Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. Compr Physiol. 2013;3:1-58.
Hollenbeck C, Reaven GM. Variations in insulin stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endorinol Metab 1987; 64: 1169-73.
Semple RK, Savage DB, Cochran EK, et al. Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32:498.
Thies R, Molina JM, Ciavaldi TP, Friendenberg GR, Olefsky JM. İnsulin receptor autophosphorylation and endogenous substrate phophorylation in human adipocytes from control, obese and NIDDM subjects. Diabetes 1990; 39: 250-8.
Cusi K, Maezono K, Osman Aet al. İnsulin resistance differantially aaffects the PI-3 kinase and MAP kinase mediated signaling in human muscle. J Clin İnvest 2000; 105: 311-20.
Shepherd PR, Kahn BB. Glucose transporters and insulin action: Implications for insulin resistance and diabetes mellitus. N Eng J Med 1999; 341: 28-257.
Eriksson J, Franssila-Kallnunki A, Ekstrand A et al. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes. N Engl J Med 1989; 321: 337-43.
McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clinics in Dermatology (2018) 36, 14–20.
Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060–68.
Eckel RH. Obesity: mechanisms and clinical management. Philadelphia (PA): Lippincott Williams & Wilkins, 2003.
Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. J Biol Chem 2002; 277: 32915–22.
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (suppl 3): 14–23.
Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944–50.
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–71.
Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140–42.
Bergman RN, Kim SP, Hsu IR, vd. Abdominal obezite: metabolik hastalık ve kardiyovasküler riskin patofizyolojisindeki rolü. Am J Med 2007; 120: S3.
Klop B, Elte JW, Cabezas MC. Obezitede dislipidemi: mekanizmalar ve potansiyel hedefler. Nutrients 2013; 5: 1218.
Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin N Am 2004; 33: 267-82.
Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-ain sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-10.
Likuni N, Kwan Lam Q, Lu L, Matarese G, Cava A. 2008. Leptin and inflammation. Curr. Immunol. Rev. 4, 70–79.
Perry RJ, Peng L, Abulizi A, Kennedy L, Cline GW, Shulman GI. 2017. Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis. J. Clin. Invest. 127, 657–669.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. 2001. The hormone resistin links obesity to diabetes. Nature 409, 307–312.
Yamauchi T, Kamon J, İto Y, et al. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762–769.
Dandona P, Aljada A, Mohanty P. İnsulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-65.
Bjontorp P. Portal adipose tissue as a generitor of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002; 51:3120.
Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003; 26:861.
Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25:1790.
Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414.
Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927.
Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31:1898.
Ford ES, Schulze MB, Pischon T, et al. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol 2008; 7:35.
Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007; 115:1806.
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am 2014; 43:1.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769.
Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812.
Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403.
Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906.
Saely CH, Koch L, Schmid F, et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006; 29:901.
Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24:695.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2:901.
Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013; 28:664.
Neuroschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007; 23: 193-8.
Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009; 29:223.
Bassi N, Karagodin I, Wang S, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med 2014; 127:1242.e1.
Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e535.
Kastorini CM, Milionis HJ, Esposito K, et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011; 57:1299.
Azadbakht L, Mirmiran P, Esmaillzadeh A, et al. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28:2823.
Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26:2261.
Ma Y, Olendzki BC, Wang J, et al. Single-component versus multicomponent dietary goals for the metabolic syndrome: a randomized trial. Ann Intern Med 2015; 162:248.
Després JP, Pouliot MC, Moorjani S, et al. Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol 1991; 261:E159.
Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549.
Lindstrom J, İlanne-Parrikka P, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-9
Knowler WC, Barrett-Conner E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.
Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388.
Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551.
McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477.